Subcutaneous delivery of FGF21 mRNA therapy reverses obesity, insulin resistance, and hepatic steatosis in diet-induced obese mice

Fibroblast growth factor 21 (FGF21) is a promising therapeutic agent for treatment of type 2 diabetes (T2D) and non-alcoholic steatohepatitis (NASH). We show that therapeutic levels of FGF21 were achieved following subcutaneous (s.c.) administration of mRNA encoding human FGF21 proteins. The efficac...

Descripción completa

Detalles Bibliográficos
Autores principales: Bartesaghi, Stefano, Wallenius, Kristina, Hovdal, Daniel, Liljeblad, Mathias, Wallin, Simonetta, Dekker, Niek, Barlind, Louise, Davies, Nigel, Seeliger, Frank, Winzell, Maria Sörhede, Patel, Sima, Theisen, Matt, Brito, Luis, Bergenhem, Nils, Andersson, Shalini, Peng, Xiao-Rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9079007/
https://www.ncbi.nlm.nih.gov/pubmed/35592498
http://dx.doi.org/10.1016/j.omtn.2022.04.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9079007/
https://www.ncbi.nlm.nih.gov/pubmed/35592498
http://dx.doi.org/10.1016/j.omtn.2022.04.010

Ejemplares similares